Project Grant K24HL180995
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $123K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Wauwatosa, WI 53226, USA
Similar Awards
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to advance the understanding of the molecular and neurobiological mechanisms underlying chronic pain in sickle cell disease (SCD) and develop effective pharmacologic treatments. The $1,103,783 award to the University of Illinois will utilize well-characterized sickle cell transgenic mouse models to study epigenetic, neurobiology, and gut microbiota...
- This $146,013 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) will be used by The Medical College of Wisconsin, Inc. to establish a large patient cohort leveraging electronic health record and administrative claims data to determine the risks of cardiopulmonary and renal end organ complications and factors associated with frequent acute care use among individuals with sickle cell disease. The award period...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $137,219 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Illinois in Chicago. The goal of this 5-year grant is to develop the skills of Dr. Santosh L. Saraf, a mid-career hematologist and physician-scientist, to mentor the next generation of junior investigators focused on sickle cell disease (SCD)-related research. The research aims to investigate genetic factors and the role of complement...
- This $1,049,682 federal Project Grant award from the National Institute of Neurological Disorders and Stroke, under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a 5-year prospective cohort study to develop and validate novel computational and clinical tools for understanding and addressing differences in pain experience and response to pain treatment among people with sickle cell disease (SCD). The study will utilize the Globin Research Network for Data and Discovery...
- The National Heart, Lung, and Blood Institute awarded a $1,045,688 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Reneurogen LLC to develop a novel drug candidate for treating vaso-occlusive crisis, pain, and other vascular complications in sickle cell disease. The funding will support research to demonstrate that the drug candidate, N-acetyl-lysyltyrosylcysteine amide (KYC), can inhibit the vicious cycle of hemoglobin polymerization, impaired red blood cell...
- This federal Project Grant award of $761,028 from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 Cardiovascular Diseases Research will support a multi-site prospective study on hypoxemia during sleep in adults with sickle cell anemia (SCA). The study aims to examine the prevalence, clinical impact, and response to treatment of sleep-related hypoxemia in this patient population across four institutions, including both urban and rural sites. Key activities will involve...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,764,145.00 to Midwestern University to conduct research on miRNA as a novel therapeutic target for pain management in sickle cell disease (SCD). The long-term goal is to develop effective pharmacological interventions to alleviate chronic pain and improve quality of life for SCD patients. The research focuses on...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded The Ohio State University a $765,931 Project Grant on August 22, 2025. This grant will fund a multi-center hybrid effectiveness-implementation trial to assess the delivery of patient-facing, evidence-based guidelines for sickle cell disease (SCD) through a mobile health (mHealth) application and educational booklets. The goal is to improve knowledge and adherence to...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides funding of $2,968,063.02 to the Children's Research Institute to conduct a randomized, double-blind, placebo-controlled Phase 2 clinical trial of intravenous citrulline for treating vaso-occlusive crisis in sickle cell disease. The study aims to determine if the administration of citrulline, which plays a role in nitric oxide production, can lead to...
- This federal Project Grant award for $111,626.00 was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage populations and their role in pulmonary hypertension associated with sickle cell disease. The 2-year research project aims to determine if targeting iron release can modify CD169+ macrophages and adaptive immune cells, and if ablation of CD169+ macrophages can inhibit the progression of...